MedTrace Logo

Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

NCT01580241 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-04-01

No results posted yet for this study

Summary

The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1

Conditions

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Courtney Houchen, MD · University of Oklahoma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-07-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01580241 on ClinicalTrials.gov